Table 7.

Changes in urinary concentrations of additional proteins in patients prescribed cisplatin-containing regimens.

	# Patients analyzed	Mean cisplatin dose	Cisplatin naïve (yes/no)	# Patients with clinical AKI	Highest mean/median fold change from baseline during the observation period	Timing of peak change	References
Calbindin	14	70 mg	Unknown	None	U: ↑ 23-fold	Day 10	36
	57	63.4 mg/m2	Mixed	n = 1	U: ↑ 8.3-fold	Day 10	31
MCP-1	11	<80 mg/m2	Unknown	n = 10 Day 3AUC-ROC: 0.85	U: ↑ 3.8-fold	Day 7	37
	57	63.4 mg/m2	Mixed	n = 1	U: ↑ 1.7-fold	Day 10	31
Clusterin	27	80 mg/m2	Yes	n = 2	U: ↑ 2.5-fold	Day 7	50
	57	63.4 mg/m2	Mixed	n = 1	U: ↑ 1.9-fold	Day 10	31
IGFBP7	45	59.9 mg/m2	No	n = 13 No difference between AKI and no AKI	U: No changeDay 1		71
IGFBP7	46	64.2 mg/m2	No	n = 1	U: No change Day 3 or 10		72
TIMP2×IGFBP7	45	59.9 mg/m2	No	n = 13AUC-ROC: 0.46	U: No change Day 1		71
TIMP2×IGFBP7	32	78 mg/m2	No	n = 4 <Day 3AUC-ROC: 0.92	NE		73
TIMP2×IGFBP7	46	64.2 mg/m2	No	n = 1	U: No changeDay 3 or 10		72
TIMP2	45	59.9 mg/m2	No	n = 13No difference between AKI and no AKI	U: ↑ 1.1-fold	Day 1	71
TIMP2	46	64.2 mg/m2	No	n = 1	U: No change Day 3 or 10		72
GST-pi	57	63.4 mg/m2	Mixed	n = 1	U: ↑ 1.6-fold	Day 10	31
IL-18	57	63.4 mg/m2	Mixed	n = 1	U: No change Day 3 or 10		31
Osteopontin	57	63.4 mg/m2	Mixed	n = 1	U: No change Day 3 or 10		31
TFF3	57	63.4 mg/m2	Mixed	n = 1	U: ↑ 2-fold	Day 10	31

AKI: acute kidney injury; AUC-ROC: area under the curve receiver operating characteristic; eGFR: estimated glomerular filtration rate; GST-pi: Glutathione-S-transferase-pi; IGFBP7: Insulin like growth factor binding protein-7; IL-18: Interleukin-18; MCP-1: monocyte chemotactic peptide-1; NE: not evaluated; S: serum; TIMP2: Tissue inhibitor of metalloproteinases-2; TFF3: Trefoil factor 3; U: urine.

Each publication provides different definitions for the diagnosis of clinical acute kidney injury.